Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 KL Ong, LK Stafford, SA McLaughlin, EJ Boyko, SE Vollset, AE Smith, ... The Lancet 402 (10397), 203-234, 2023 | 645 | 2023 |
Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies S Xu, I Ilyas, PJ Little, H Li, D Kamato, X Zheng, S Luo, Z Li, P Liu, J Han, ... Pharmacological reviews 73 (3), 924-967, 2021 | 529 | 2021 |
Flavonoid biosynthetic pathways in plants: Versatile targets for metabolic engineering SM Nabavi, D Šamec, M Tomczyk, L Milella, D Russo, S Habtemariam, ... Biotechnology advances 38, 107316, 2020 | 450 | 2020 |
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019 KB Tran, JJ Lang, K Compton, R Xu, AR Acheson, HJ Henrikson, ... The Lancet 400 (10352), 563-591, 2022 | 435 | 2022 |
Cardiovascular actions and therapeutic potential of tanshinone IIA S Gao, Z Liu, H Li, PJ Little, P Liu, S Xu Atherosclerosis 220 (1), 3-10, 2012 | 379 | 2012 |
Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics Z Li, S Xu, P Liu Acta Pharmacologica Sinica 39 (5), 802-824, 2018 | 347 | 2018 |
Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 BS Sheena, L Hiebert, H Han, H Ippolito, M Abbasi-Kangevari, ... The lancet Gastroenterology & hepatology 7 (9), 796-829, 2022 | 328 | 2022 |
Transforming growth factor-β signalling: role and consequences of Smad linker region phosphorylation D Kamato, ML Burch, TJ Piva, HB Rezaei, MA Rostam, S Xu, W Zheng, ... Cellular signalling 25 (10), 2017-2024, 2013 | 314 | 2013 |
LOX-1 in atherosclerosis: biological functions and pharmacological modifiers S Xu, S Ogura, J Chen, PJ Little, J Moss, P Liu Cellular and Molecular Life Sciences 70, 2859-2872, 2013 | 305 | 2013 |
Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics X Feng, A Sureda, S Jafari, Z Memariani, D Tewari, G Annunziata, ... Theranostics 9 (7), 1923, 2019 | 297 | 2019 |
Curcumin, the golden spice in treating cardiovascular diseases H Li, A Sureda, HP Devkota, V Pittalà, D Barreca, AS Silva, D Tewari, ... Biotechnology advances 38, 107343, 2020 | 280 | 2020 |
Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020 D Bryazka, MB Reitsma, MG Griswold, KH Abate, C Abbafati, ... The Lancet 400 (10347), 185-235, 2022 | 256 | 2022 |
Antioxidants in cardiovascular therapy: panacea or false hope? K Goszcz, SJ Deakin, GG Duthie, D Stewart, SJ Leslie, IL Megson Frontiers in cardiovascular medicine 2, 29, 2015 | 217 | 2015 |
Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies S Xu, I Ilyas, J Weng Acta Pharmacologica Sinica 44 (4), 695-709, 2023 | 193 | 2023 |
Evaluation of foam cell formation in cultured macrophages: an improved method with Oil Red O staining and DiI-oxLDL uptake S Xu, Y Huang, Y Xie, T Lan, K Le, J Chen, S Chen, S Gao, X Xu, X Shen, ... Cytotechnology 62, 473-481, 2010 | 177 | 2010 |
Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-κB signaling pathway Q Jiang, P Liu, X Wu, W Liu, X Shen, T Lan, S Xu, J Peng, X Xie, H Huang Molecular and cellular endocrinology 331 (1), 34-40, 2011 | 166 | 2011 |
Tanshinone II-A: new perspectives for old remedies S Xu, P Liu Expert opinion on therapeutic patents 23 (2), 149-153, 2013 | 157 | 2013 |
Targeting mechanosensitive transcription factors in atherosclerosis N Niu, S Xu, Y Xu, PJ Little, ZG Jin Trends in pharmacological sciences 40 (4), 253-266, 2019 | 155 | 2019 |
ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: an updated review X Feng, L Zhang, S Xu, A Shen Progress in lipid research 77, 101006, 2020 | 154 | 2020 |
Atherosclerosis is an epigenetic disease S Xu, J Pelisek, ZG Jin Trends in Endocrinology & Metabolism 29 (11), 739-742, 2018 | 147 | 2018 |